Dose adjustment may be required for patients who have kidney disease. Phenazopyridine should not be used in patients whose creatinine clearance is less than 50 ml/min. Phenazopyridine should be administered every 8-16 hours in patients whose creatinine clearance is between 50-80 ml/min.
The usual recommended dose for children and adolescents is 4 mg/kg orally three times daily after meals. The child's pediatric doctor should calculate the dose. Treatment should not exceed 2 days when used in-combination with an antibacterial agent.
DRUG INTERACTIONS: No clinical significant drug interactions have been reported with phenazopyridine use.
PREGNANCY: Phenazopyridine is classified as FDA pregnancy risk category B (animal studies show no harm to fetuses but there are no well-controlled studies in pregnant women). Reproduction studies in rats at doses up to 50 mg/kg//day have shown no evidence of fetal harm. However, as with all drugs, phenazopyridine should be used in pregnancy only if clearly needed.
NURSING MOTHERS: It is not known if phenazopyridine is excreted in breast milk.
SIDE EFFECTS: Common side effects of phenazopyridine treatment affecting up to 10 percent of patients are:
Rare but serious side effects associated with phenazopyridine (occurring in <1%) include:
REFERENCE: FDA Prescribing Information.
Quick GuideUrinary Tract Infections (Bladder Infection): UTI Symptoms, Treatment, Causes
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.